Vaxcyte Inc. (PCVX): Price and Financial Metrics


Vaxcyte Inc. (PCVX): $21.69

-0.07 (-0.32%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

PCVX Stock Price Chart Interactive Chart >

Price chart for PCVX

PCVX Price/Volume Stats

Current price $21.69 52-week high $27.44
Prev. close $21.76 52-week low $16.78
Day low $21.13 Volume 311,500
Day high $22.09 Avg. volume 343,589
50-day MA $22.66 Dividend yield N/A
200-day MA $22.92 Market Cap 1.26B

Vaxcyte Inc. (PCVX) Company Bio


Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.


PCVX Latest News Stream


Event/Time News Detail
Loading, please wait...

PCVX Latest Social Stream


Loading social stream, please wait...

View Full PCVX Social Stream

Latest PCVX News From Around the Web

Below are the latest news stories about Vaxcyte Inc that investors may wish to consider to help them evaluate PCVX as an investment opportunity.

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

-- Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 -- -- Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 -- -- VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection -- SAN CARLOS, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequence

Yahoo | February 23, 2022

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

SAN CARLOS, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

GlobeNewswire | February 17, 2022

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

SAN CARLOS, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

GlobeNewswire | February 10, 2022

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced the appointment of Grant Pickering to its Board of Directors. Mr. Pickering is Chief Executive Officer, co-founder and member of the Board of Directors at Vaxcyte, Inc. (NASDAQ: PCVX), a vaccine innovation company engineering high-fidelity vaccines to prote

Yahoo | January 31, 2022

Vaxcyte Raises $100M Via Equity To Fund Development Of Lead Pneumococcal Vaccine Candidate

Vaxcyte Inc (NASDAQ: PCVX ) priced its previously announced offering of common stock and pre-funded warrants at $20.00 per share, and $19.999 per underlying share, respectively. Vaxcyte is selling 2.5 million shares and pre-funded warrants to purchase 2.5 million shares of common stock in the offering. The aggregate gross proceeds to Full story available on Benzinga.com

Benzinga | January 13, 2022

Read More 'PCVX' Stories Here

PCVX Price Returns

1-mo -0.96%
3-mo -15.54%
6-mo -9.28%
1-year -4.83%
3-year N/A
5-year N/A
YTD -8.83%
2021 -10.46%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6283 seconds.